Pharmiva Past Earnings Performance
Past criteria checks 0/6
Pharmiva's earnings have been declining at an average annual rate of -24.1%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 63.1% per year.
Key information
-24.1%
Earnings growth rate
21.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 63.1% |
| Return on equity | -138.6% |
| Net Margin | -502.5% |
| Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Pharmiva makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 23 | 4 | -21 | 23 | 0 |
| 31 Mar 23 | 5 | -23 | 24 | 0 |
| 31 Dec 22 | 4 | -24 | 25 | 0 |
| 30 Sep 22 | 3 | -23 | 25 | 0 |
| 30 Jun 22 | 3 | -24 | 25 | 0 |
| 31 Mar 22 | 2 | -21 | 22 | 0 |
| 31 Dec 21 | 2 | -21 | 22 | 0 |
| 30 Sep 21 | 2 | -19 | 19 | 0 |
| 30 Jun 21 | 2 | -18 | 18 | 0 |
| 31 Mar 21 | 1 | -16 | 15 | 0 |
| 31 Dec 20 | 1 | -14 | 13 | 0 |
| 31 Dec 19 | 2 | -11 | 12 | 0 |
| 30 Apr 19 | 5 | -4 | 8 | 0 |
| 30 Apr 18 | 3 | -2 | 5 | 0 |
Quality Earnings: 958 is currently unprofitable.
Growing Profit Margin: 958 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 958 is unprofitable, and losses have increased over the past 5 years at a rate of 24.1% per year.
Accelerating Growth: Unable to compare 958's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 958 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.8%).
Return on Equity
High ROE: 958 has a negative Return on Equity (-138.59%), as it is currently unprofitable.